Bai Hongyun, Hu Xiuyun, Meng Caiwen, Zu Wenjing, Qiu Xue, Liu Jie, Liu Jingjing, Liu Jianyu, Wang Xiaoliang, Li Meichen
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin, 300301, PR China.
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin, 300301, PR China; School of Traditional Chinese Medicine, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, PR China.
J Ethnopharmacol. 2025 Aug 6;353(Pt B):120366. doi: 10.1016/j.jep.2025.120366.
Cotinus coggygria Scop. (syn Rhus cotinus L.), a plant with a longstanding medicinal history, has been traditionally employed in Asian ethnomedicine for the management of hepatic disorders and gastrointestinal ailments.
This review systematically evaluates the ethnomedicinal applications, phytochemical profile, pharmacological properties, clinical relevance, and safety data of C. coggygria to establish a foundation for its rational development as a therapeutic agent in TCM.
A thorough literature search was carried out in several main databases (ScienceDirect, SciFinder, Wan Fang Database, Web of Science, PubMed, CNKI, Google Scholar and Baidu Scholar) and botanical nomenclature databases (The Plant List). The search used keywords such as "Cotinus coggygria," "Rhus coggygria," and all the taxonomic synonyms of this species.
Phytochemical investigations of C. coggygria have identified over 300 constituents, with 57 purified compounds characterized to date. Phenolic derivatives dominate the isolated compounds, while terpenoid-rich volatile oils constitute the majority of leaf components. Bioactivity assessments of C. coggygria reveal broad therapeutic potential, including hepatoprotective, antioxidant, cytotoxic, anti-inflammatory, antimicrobial, and anticoagulant effects. Flavonoid constituents emerge as the primary bioactive contributors, supported by mechanistic studies.
Despite centuries of ethnomedicinal use with minimal documented adverse effects, current clinical validation of C. coggygria remains limited to hepatic disorders. Critical research gaps persist in elucidating molecular mechanisms, dose-response relationships, and long-term safety profiles. Robust preclinical investigations and standardized clinical trials are imperative to substantiate the therapeutic promise of this species.
黄栌(学名:Cotinus coggygria Scop.,异名:Rhus cotinus L.)是一种有着悠久药用历史的植物,在亚洲民族医学中传统上用于治疗肝脏疾病和胃肠道疾病。
本综述系统评价黄栌的民族药用应用、植物化学特征、药理特性、临床相关性和安全性数据,为其作为中药治疗剂的合理开发奠定基础。
在几个主要数据库(ScienceDirect、SciFinder、万方数据库、Web of Science、PubMed、中国知网、谷歌学术和百度学术)以及植物命名数据库(植物名录)中进行了全面的文献检索。检索使用了“黄栌”“Rhus coggygria”以及该物种所有分类学同义词等关键词。
对黄栌的植物化学研究已鉴定出300多种成分,迄今有57种纯化化合物得到表征。酚类衍生物在分离出的化合物中占主导地位,而富含萜类的挥发油构成了叶片成分的大部分。黄栌的生物活性评估显示出广泛的治疗潜力,包括保肝、抗氧化、细胞毒性、抗炎、抗菌和抗凝作用。黄酮类成分是主要的生物活性成分,机理研究也证实了这一点。
尽管黄栌经过了数百年的民族药用且不良反应记录极少,但目前其临床验证仍仅限于肝脏疾病。在阐明分子机制、剂量反应关系和长期安全性方面仍存在重大研究空白。必须进行有力的临床前研究和标准化临床试验,以证实该物种的治疗前景。